Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipid-altering agents: the future.

A S Wierzbicki1

  • 1St Thomas' Hospital Campus, London, UK. anthony.wierzbicki@kcl.ac.uk

International Journal of Clinical Practice
|December 21, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute kidney injury: prevention, detection, and management. Summary of updated NICE guidance for adults receiving iodine-based contrast media.

Clinical radiology·2021
Same author

Further options for treating lipids in people with diabetes: targeting LDL-cholesterol and beyond.

Diabetic medicine : a journal of the British Diabetic Association·2018
Same author

Mind the gap - surviving in the modern world.

International journal of clinical practice·2016
Same author

Familial Hypercholesterolaemia in the Era of Genetic Testing.

Current cardiology reports·2016
Same author

Safety of long-term restrictive diets for peroxisomal disorders: vitamin and trace element status of patients treated for Adult Refsum Disease.

International journal of clinical practice·2016
Same author

Improving the odds: ezetimibe and cardiovascular disease.

International journal of clinical practice·2015
Same journal

RETRACTION: Prediction of Arrhythmia Recurrence after Atrial Fibrillation Ablation in Patients with Normal Anatomy of the Left Atrium.

International journal of clinical practice·2025
Same journal

Clinical Outcomes Based on the Attainment of Low-Density Lipoprotein Cholesterol Targets in Patients with Acute Coronary Syndrome in Real-World Practice.

International journal of clinical practice·2025
Same journal

Knowledge and Awareness of Osteoporosis: A Survey of Physical Therapy Providers in Saudi Arabia.

International journal of clinical practice·2024
Same journal

Efficacy and Safety of Pericapsular Nerve Group Block for Hip Fracture Surgery under Spinal Anesthesia: A Meta-Analysis.

International journal of clinical practice·2024
Same journal

The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases.

International journal of clinical practice·2024
Same journal

Blood Features Associated with Viral Infection Severity: An Experience from COVID-19-Pandemic Patients Hospitalized in the Center of Iran, Yazd.

International journal of clinical practice·2024
See all related articles

Novel lipid-altering therapies are emerging to combat atherosclerosis. This review covers new drug developments and targets, offering hope for improved treatment strategies and potential drug combinations.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Lipid-lowering interventions are proven to reduce atherosclerosis and its complications.
  • Atherosclerosis remains a significant global health concern requiring advanced therapeutic strategies.

Purpose of the Study:

  • To summarize novel developments in lipid-altering therapies currently under development.
  • To discuss emerging therapeutic targets for atherosclerosis treatment.

Main Methods:

  • Review of current research on novel lipid-altering drug candidates.
  • Identification of various molecular targets for therapeutic intervention.
  • Inclusion of compounds that have reached animal model trials.

Main Results:

  • Several novel lipid-altering therapies are in development.

Related Experiment Videos

  • Multiple distinct molecular targets are being explored for atherosclerosis.
  • Compounds targeting squalene synthase, microsomal transfer protein, and others show promise.

    • Conclusions:

    • The field of lipid-altering drugs is rapidly advancing.
    • Potential synergies exist between new and established compounds.
    • These developments offer promising avenues for novel atherosclerosis treatments.